Cargando…

Erratum to: A placebo-controlled, double-blind, randomized, multicenter study to assess the effects of dronedarone 400 mg twice daily for 12 weeks on atrial fibrillation burden in subjects with permanent pacemakers

Detalles Bibliográficos
Autores principales:	Ezekowitz, Michael D., Ellenbogen, Kenneth A., DiMarco, John P., Kaszala, Karoly, Boddy, Alexander, Geba, Gregory P., Koren, Andrew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2015
Materias:	Erratum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643575/ https://www.ncbi.nlm.nih.gov/pubmed/25862556 http://dx.doi.org/10.1007/s10840-015-0001-9

Ejemplares similares

A placebo-controlled, double-blind, randomized, multicenter study to assess the effects of dronedarone 400 mg twice daily for 12 weeks on atrial fibrillation burden in subjects with permanent pacemakers
por: Ezekowitz, Michael D., et al.
Publicado: (2015)

Practical guide to choosing dabigatran 150 mg twice daily or apixaban 5 mg twice daily for patients with atrial fibrillation
por: Kobayashi, Zen, et al.
Publicado: (2019)

Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection: Week 96 Results From ONCEMRK, a Randomized, Double-Blind, Noninferiority Trial
por: Cahn, Pedro, et al.
Publicado: (2018)

Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100, 200/150, and 200/50 mg twice daily in HIV-negative volunteers
por: Jackson, AGA, et al.
Publicado: (2010)

A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50 mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly and acitretin, and acitretin alone in patients with moderate to severe psoriasis
por: Lee, Joo-Heung, et al.
Publicado: (2016)

Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers
por: Chiquette, Elaine, et al.
Publicado: (2012)

Efavirenz 400 mg daily remains non-inferior to 600 mg: 96 week data from the double-blind, placebo-controlled ENCORE1 study
por: Carey, Dianne
Publicado: (2014)

Variability in and predictors of glycaemic responses after 24 weeks of treatment with exenatide twice daily and exenatide once weekly
por: Shaw, Jonathan E., et al.
Publicado: (2017)

Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: A randomised controlled trial in patients with osteoarthritis
por: Fleischmann, Roy, et al.
Publicado: (2008)

Comparative Efficacy of Super Bioavailable Itraconazole Capsules 50 mg vs 65 mg Twice Daily in the Management of Glabrous Tinea
por: Shah, Bela, et al.
Publicado: (2023)

Clinical Acceptability Of Trimetazidine Modified-Release 80 mg Once Daily Versus Trimetazidine Modified-Release 35 mg Twice Daily In Stable Angina Pectoris
por: Pozdnyakov, Yuri M.
Publicado: (2018)

Economic impact of the use of rifaximin 550 mg twice daily for the treatment of overt hepatic encephalopathy in Italy
por: Roggeri, Daniela Paola, et al.
Publicado: (2017)

Twice or Thrice Weekly versus Daily Thyroxine in Hypothyroid Fasting Ramadan: A Pilot Study
por: Elsherbiny, Tamer Mohamed
Publicado: (2022)

Paradoxical reflex bradycardia after epinephrine infusion for arrhythmia induction in the electrophysiology laboratory
por: Larsen, Timothy R., et al.
Publicado: (2018)

Comparative Safety and Effectiveness of Sotalol Versus Dronedarone After Catheter Ablation for Atrial Fibrillation
por: Wharton, John Marcus, et al.
Publicado: (2022)

Is Twice-weekly Maintenance Hemodialysis Justified?
por: Mendonca, Satish, et al.
Publicado: (2021)

Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients
por: Nadler, Jeffrey P, et al.
Publicado: (2003)

Dronedarone in the management of atrial fibrillation
por: Saleem, TS Mohamed, et al.
Publicado: (2010)

Dronedarone-induced photoallergic reaction
por: Amar, Levy, et al.
Publicado: (2020)

Impact of Dronedarone Treatment on Healthcare Resource Utilization in Patients with Atrial Fibrillation/Flutter
por: Kim, Michael H., et al.
Publicado: (2014)

The Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide 400 μg Administered by Inhalation as Single and Multiple (Twice Daily) Doses in Healthy Chinese Participants
por: Li, Weimin, et al.
Publicado: (2023)

Study of twice-weekly injections of Teriparatide by comparing efficacy with once-weekly injections in osteoporosis patients: the TWICE study
por: Sugimoto, T., et al.
Publicado: (2019)

Twice-daily Budesonide 2-mg Foam Induces Complete Mucosal Healing in Patients with Distal Ulcerative Colitis
por: Naganuma, Makoto, et al.
Publicado: (2016)

Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily1
por: Best, J H, et al.
Publicado: (2009)

Twice‐Daily Doravirine Overcomes the Interaction Effect from Once‐Weekly Rifapentine and Isoniazid in Healthy Volunteers
por: Lam, Edwin, et al.
Publicado: (2020)

Efficacy of once-weekly and twice-weekly injections of teriparatide by patient characteristics: A post hoc analysis of the TWICE study
por: Sugimoto, Toshitsugu, et al.
Publicado: (2021)

Reasons for Delay in Permanent Pacemaker Insertion
por: Mackintosh, A F, et al.
Publicado: (1986)

Can we explore AF–pacemakers’ relationship using clinical and echocardiographic parameters in patients with permanent pacemaker? (Echocardiography and subclinical AF in permanent pacemaker)
por: EL-Dosouky, Ibtesam I., et al.
Publicado: (2022)

Hemodynamic response and safety of vasodilator stress cardiovascular magnetic resonance in patients with permanent pacemakers or implantable cardioverter‐defibrillators
por: Miller, Lauren, et al.
Publicado: (2022)

Is dronedarone really safer than amiodarone?
por: Shah, Shreya M., et al.
Publicado: (2012)

At-Home Telemedicine Controlled taVNS Twice Daily for 4 weeks is Feasible and Safe for Long COVID Symptoms.
por: Huffman, Sarah, et al.
Publicado: (2021)

Pharmacokinetic and Pharmacodynamic Comparison of Once‐Daily Efavirenz (400 mg vs. 600 mg) in Treatment‐Naïve HIV‐Infected Patients: Results of the ENCORE1 Study
por: Dickinson, L, et al.
Publicado: (2015)

A Review of Temporary Permanent Pacemakers and a Comparison with Conventional Temporary Pacemakers
por: Suarez, Keith, et al.
Publicado: (2019)

Influence of demographic and disease parameters on virological response to once- vs twice-daily darunavir/ritonavir (DRV/r) at week 48 in ODIN
por: Sension, M, et al.
Publicado: (2010)

A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study)
por: Kumar, Princy N, et al.
Publicado: (2009)

Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study
por: Dickinson, Laura, et al.
Publicado: (2015)

Severe erythroderma secondary to permanent pacemaker allergy
por: Stringer, Bryan F., et al.
Publicado: (2021)

Arrhythmia diagnosis using a permanent pacemaker
por: Demirtas, Abdullah Orhan, et al.
Publicado: (2022)

ALESIA 5-Year Update: Alectinib at 600 mg Twice Daily Gives Lorlatinib a Run for Its Money in Asia
por: Lee, Alexandria T M, et al.
Publicado: (2023)

Once– versus twice–daily tacrolimus: are the formulations equivalent?
por: Ciszek, Michał
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_8idvd340iddgqfkmgoh4bk5oem